NeoGenomics, Inc. (NG9)
XSTU
Closed
Oct 8, 2026
Day's Range
13.7752 wk Range
6.15Overview - NG9 - NeoGenomics, Inc.
Key Statistics
Valuation
Enterprise Value
249.83M
P/E (Trailing)
‪-20.33‬
PEG Ratio
‪0.19‬
Price / Book
‪2.81‬
EV / EBITDA
‪-22.84‬
Profitability
Gross Margin
‪45.56%‬
Profit Margin
‪43.21%‬
Operating Margin
‪-14.64%‬
Return on Assets
‪-7.94%‬
Return on Equity
‪-12.91%‬
Ownership
Shares Outstanding
127.91M
Price stats
50-Day Avg
‪14.36‬
200-Day Avg
‪10.35‬
Peers - NG9 - NeoGenomics, Inc.
Peer Comparison
Compared with companies in Diagnostics & Research listed on XSTU.
- NG9XSTUNeoGenomics, Inc.+60.85%52-week change-20.33P/E (Trailing)‪43.21%‬Profit Margin
- NL0XSTUGRAIL, Inc.+55.16%52-week change-9.98P/E (Trailing)‪-236.94%‬Profit Margin
- 1K9XSTUCareDx Inc.+77.34%52-week change-138.75P/E (Trailing)‪67.55%‬Profit Margin
- 0MEXSTUTwist Bioscience Corporation+85.77%52-week change-123.50P/E (Trailing)‪50.72%‬Profit Margin
- ILUXSTUIllumina Inc.+67.25%52-week change43.70P/E (Trailing)‪66.08%‬Profit Margin
- RV6XSTUCharles River Laboratories International, Inc.+51.37%52-week change-87.94P/E (Trailing)‪32.95%‬Profit Margin
- WX8XSTUWuXi AppTec Co., Ltd.+48.80%52-week change3.50P/E (Trailing)‪47.63%‬Profit Margin
Profile Summary - NG9 - NeoGenomics, Inc.
About
NeoGenomics, Inc. is a cancer diagnostics company focused on oncology testing and information services. The company provides a broad menu of laboratory solutions across the cancer care continuum, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, flow cytometry,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
